Merck & Co Inc. (MRK) out-licensed a portfolio of gene therapy products into a new Finnish company, FKD Therapies OY, which was co-founded by Nigel Parker, former CEO of UK gene therapy specialist firmArk Therapeutics plc.
Since its formation in February, FKD has raised $16 million in private funding underwritten by German firm Wolbern Invest, with backing from Finland’s public funding agency for technology and innovation, TEKES.
Read more: http://seekingalpha.com